Bioatla Inc (BCAB)

Currency in USD
1.400
+0.110(+8.53%)
Delayed Data·
BCAB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.2201.550
52 wk Range
1.07059.500
Key Statistics
Prev. Close
1.29
Open
1.55
Day's Range
1.22-1.55
52 wk Range
1.07-59.5
Volume
2.75K
Average Vol. (3m)
39.9K
1-Year Change
-97.5862%
Book Value / Share
-26.17
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BCAB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Bioatla Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Rodman & Renshaw
Buy4.00+185.71%-New CoverageJan 13, 2026

Bioatla Inc SWOT Analysis


Strategic Crossroads
Discover BioAtla's strategic initiatives, including workforce reductions and partnership pursuits, aimed at extending its runway to key clinical milestones
Pivotal Data Awaited
Learn about the critical upcoming ESMO conference, where BA3182 data could significantly impact BioAtla's future prospects and valuation
Financial Tightrope
Delve into BioAtla's financial challenges, including rapid cash burn and elevated expenses, as it races to advance its promising oncology pipeline
CAB Technology Edge
Explore BioAtla's innovative conditionally active biologics platform, aiming to revolutionize cancer treatment with enhanced efficacy and reduced side effects
Read full SWOT analysis

Bioatla Inc Earnings Call Summary for Q3/2025

  • Bioatla reported Q3 2025 EPS of -$0.27, meeting forecasts, but stock fell 4.09% to $0.67 amid investor concerns over increased net losses of $15.8M and low cash reserves of $8.3M.
  • Despite cost management efforts reducing R&D and G&A expenses, the company's net loss increased from $10.6M in Q3 2024, raising questions about financial sustainability.
  • Bioatla achieved FDA alignment for a phase 3 trial in OPSCC, with CEO Jay Short announcing plans to begin enrollment early next year and key clinical readouts expected in H1 2026.
  • Management plans to finalize a strategic transaction by year-end, focusing on prioritized programs while addressing the company's precarious cash position.
Last Updated: 11/13/2025, 05:22 PM
Read Full Transcript

Earnings

Latest Release
Nov 16, 2026
EPS / Forecast
-4.74 / -0.14
Revenue / Forecast
250K / --
EPS Revisions
Last 90 days

BCAB Income Statement

Compare BCAB to Peers and Sector

Metrics to compare
BCAB
Peers
Sector
Relationship
P/E Ratio
−0.1x−1.1x−0.2x
PEG Ratio
0.000.010.00
Price / Book
0.0x0.4x2.6x
Price / LTM Sales
0.2x13.1x2.7x
Upside (Analyst Target)
-893.1%72.2%
Fair Value Upside
Unlock−26.1%12.4%Unlock

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
20.15K1.21%27.28K
Other Institutional Investors
367.41K22.05%497.48K
Public Companies & Retail Investors
1.28M76.74%1.73M
Total
1.67M100.00%2.26M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Acorn Bioventures6.49%108,126146
Acorn Bioventures, L.P.5.80%96,702131

FAQ

What Is the Bioatla (BCAB) Stock Price Today?

The Bioatla stock price today is 1.400 USD.

What Stock Exchange Does Bioatla Trade On?

Bioatla is listed and trades on the OTC Markets.

What Is the Stock Symbol for Bioatla?

The stock symbol for Bioatla is "BCAB."

What Is the Bioatla Market Cap?

As of today, Bioatla market cap is 2.330M USD.

What Is Bioatla's Earnings Per Share (TTM)?

The Bioatla EPS (TTM) is -15.65.

From a Technical Analysis Perspective, Is BCAB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Bioatla Stock Split?

Bioatla has split 1 times.

How Many Employees Does Bioatla Have?

Bioatla has 41 employees.

What is the current trading status of Bioatla (BCAB)?

As of Nov 20, 2026, Bioatla (BCAB) is trading at a price of 1.400 USD, with a previous close of 1.290 USD. The stock has fluctuated within a day range of 1.220 USD to 1.550 USD, while its 52-week range spans from 1.070 USD to 59.500 USD.

What Is the BCAB After Hours Price?

BCAB's last after hours stock price is 1.711 USD, the stock has decreased by -0.189, or -9.940%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.